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Abstract
In eukaryotes, double-stranded (ds) RNA induces
sequence-specific inhibition of gene expression re-
ferred to as RNA interference (RNAi). We exploited
RNAi to define the role of HER2/neu in the neoplastic
proliferation of human breast cancer cells. We trans-
fected SK-BR-3, BT-474, MCF-7, and MDA-MB-468
breast cancer cells with short interfering RNA (siRNA)
targeted against human HER2/neu and analyzed
the specific inhibition of HER2/neu expression by
Northern and Western blots. Transfection with HER2/
neu–specific siRNA resulted in a sequence-specific
decrease in HER2/neu mRNA and protein levels. More-
over, transfection with HER2/neu siRNA caused cell
cycle arrest at G0/G1 in the breast cancer cell lines SK-
BR-3 and BT-474, consistent with a powerful RNA
silencing effect. siRNA treatment resulted in an anti-
proliferative and apoptotic response in cells over-
expressing HER2/neu, but had no influence in cells
with almost no expression of HER2/neu proteins like
MDA-MB-468 cells. These data indicate that HER2/neu
function is essential for the proliferation of HER2/neu–
overexpressing breast cancer cells. Our observations
suggest that siRNA targeted against human HER2/neu
may be valuable tools as antiproliferative agents that
display activity against neoplastic cells at very low
doses.
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Introduction
The HER2/neu gene encodes a transmembrane tyrosine
kinase with close homology to the epidermal growth factor
receptor (EGFR) [1]. Previous studies have demonstrated
overexpression of the HER2/neu gene and deregulation of
the formation and activation of HER2 receptor heterodimers
in a high proportion of breast cancer cells [2–6]. Amplified
HER2/neu sequences have been detected in early-stage
breast cancer cells, and experimental evidence suggests
that amplification of HER2/neu sequences leads to malig-
nant transformation [7]. These observations led to the
clinical development of trastuzumab (Herceptin; Genentech,
South San Francisco, CA), amonoclonal IgG1 class humanized
murine antibody that binds specifically to the extracellular
domain of the HER2/neu protein [8]. Trastuzumab received
US marketing approval in 1998 as a treatment for metastatic
breast cancer in patients whose tumors overexpress the HER2
protein [9]. However, there are risks of cardiomyopathy and
hypersensitivity reactions associated with the use of trastuzu-
mab [10], and there remains a need for alternative therapies.
RNA interference (RNAi) has become an excellent ap-
proach for the targeted silencing of gene expression in plants
and invertebrates [11,12]. In this approach, 21- to 23-nucleotide
(nt) short interfering RNA (siRNA) complementary to the tar-
geted gene are processed from a long dsRNA precursor by the
Dicer enzyme and effectively silence the targeted gene by
binding to complementary mRNA and triggering mRNA elimi-
nation [12–16]. Elbashir et al. [18] demonstrated that transfec-
tion of synthetic 21-nt siRNA duplexes into mammalian cells
efficiently inhibits endogenous gene expression in a sequence-
specific manner. Strategies based on synthetic siRNA have
since been used to silence various cancer-relevant genes such
as bcr/abl and polo-like kinase [18–20].
We designed siRNA targeting different regions within the
open reading frame of the human HER2/neu mRNA and
analyzed their ability to silence the expression of the HER2/
neu gene in breast cancer cells overexpressing the HER2/neu
gene. In addition, we examined the impact of HER2/neu gene
modulation on the biology of HER2/neu–positive cells.
Materials and Methods
siRNA
siRNA were designed according to Elbashir et al. and
purchased from Dharmacon Research, Inc. (Lafayette, CO).
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Four different regions within the HER2/neu gene (NCBI
accession no. M11730) were used: siRNA-1 (positions
1255–1277), siRNA-2 (positions 3386–3408), siRNA-3
(positions 3563–3585), and siRNA-4 (positions 3682–
3704). siRNA-2S (scrambled) representing siRNA-2 and
siRNA-4S (scrambled) siRNA-4 as random sequences
was used as controls. All siRNA contain a 19-bp double-
stranded (ds) sequence and symmetric 3V overhangs of two
deoxythymidines.
Antibodies
Monoclonal HER2/neu antibodies for Western blots and
indirect immunofluorescence were obtained from Oncogene
(Boston). Cyclin B1, cdc2, and caspase 3 monoclonal anti-
bodies for Western blots were from Santa Cruz (Heidelberg,
Germany), and b-actin monoclonal antibodies were from
Sigma (Deisenhofen, Germany). Goat antimouse secondary
antibodies for Western blots were purchased from Santa
Cruz.
Cell Culture
Breast cancer cell lines MCF-7, BT-474, and MD-MB-468
cells were purchased from DSMZ (Braunschweig, Ger-
many), and SK-BR-3 was from ATCC (Manassas, VA). Cell
culture was performed according to the supplier’s instruc-
tions. FCS was purchased from PAA Laboratories (Co¨lbe,
Germany). RPMI 1640, phosphate-buffered saline (PBS),
OPTI-MEM I (serum-free cell medium), Oligofectamine, glu-
tamine, penicillin/streptomycin, and trypsin were purchased
from Invitrogen (Karlsruhe, Germany). McCoy’s 5A was from
Biochrome (Berlin, Germany).
In Vitro Transfection of siRNA
Cells were transfected with siRNA using the Oligofect-
amine protocol according to Elbashir et al.’s and the
manufacturer’s instructions using 0.73% (vol/vol) of Oligo-
fectamine. One day prior to transfection, 2  105 cells per
six-well plate were seeded without antibiotics, corresponding
to a density of 30% to 40% at the time of transfection. In most
experiments, cells were treated with siRNA-1–4, siRNA-S2,
or siRNA-S4 at a concentration of 56 nM. Control cells were
incubated with OPTI-MEM I alone, or with OPTI-MEM I and
Oligofectamine (mock-transfected cells), or with OPTI-MEM
I and Oligofectamine plus siRNA-2S or siRNA-4S. To eval-
uate the effect of HER2/neu–specific siRNA, cells were
treated with one of the four different HER2/neu–specific
siRNA (plus OPTI-MEM I and Oligofectamine). After each
treatment, cells were incubated at 37jC for 4 hours followed
by addition of fresh culture medium (one third of the trans-
fection volume) with 3 FCS.
Cells were harvested 24 and 48 hours after transfection
for protein andmRNA analysis; 24, 48, 72, and 96 hours after
transfection for indirect immunofluorescence and determina-
tion of proliferation rates; 72 hours after transfection for cell
cycle analysis; and 96 hours after transfection for the apo-
ptosis assay.
RNA Preparation and Northern Blots
To isolate total RNA, an RNeasy minikit (Qiagen, Hilden,
Germany) was used according to the manufacturer’s proto-
col. Radiolabeling of antisense strands for HER2/neu and b-
actin was performed using 250 mCi of [a-P32]dCTP (6000 Ci/
mmol; 1 Ci = 37 GBq) for each reaction, 50 mM of each other
dNTP, and 10 pmol (each) of primer HER2/neu–low (5V-
caagtgctccatgcccagacc-3V) corresponding to positions 901
to 1200 (NCBI accession no. M11730) within the open
reading frame of HER2/neu– or b-actin-2– low (5V-catgagg-
tagtcagtcaggtc-3V) as described previously [21]. Probes
corresponding to positions 901 to 1200 within the HER2/
neu gene were generated by polymerase chain reaction
(PCR). Northern blotting, hybridizations, and standardiza-
tions were carried out as reported [20].
Western Blot Analysis
For Western blotting, cells were lysed with RIPA buffer
(150 mM NaCl, 50 mM Tris base pH 8.0, 1 mM EDTA, 0.5%
sodium deoxycholate, 1% NP40, 0.1% sodium dodecyl
sulfate, 1 mM DTT, 1 mM PMSF, and 1 mM Na3VO4)
supplemented with Complete Protease Inhibitor Tablets
(Mannheim, Roche, Germany). Lysis and determination of
protein concentration were done as described [23]. Twenty-
five micrograms of total protein was separated on a 10%
sodium dodecyl sulfate polyacrylamide gel followed by trans-
fer (140 mA for 2 hours) to an Immobilon-P membrane
(Millipore, Bedford, MA). Membranes were incubated for
1 hour in 5% skim milk in PBS with monoclonal antibodies
(HER2/neu: 0.625 mg/ml; b-actin: 1:40,000; cyclin B1:
1:1000; cdc2: 1:1000; caspase 3: 1:1000) followed by incu-
bation with goat antimouse secondary antibodies (1:2.000)
for 30 minutes in 5% skim milk in PBS. Proteins were
visualized as described previously [23]. Standardization
and quantification were carried out as reported previously
[19]. Values were given in percentage compared to the
mock-transfected cells.
Determination of Cell Proliferation
After siRNA treatment, cell numbers were determined
using a hemacytometer. Cell viability was assessed by
trypan blue staining. The number of ‘‘control’’ cells (mock-
transfected) at each time point was used as reference. Each
transfection was carried out at least three times. t-tests were
performed with two-sided P values.
Indirect Immunofluorescence
Indirect immunofluorescence, DNA staining, and visuali-
zation were carried out as described [23,24]. Monoclonal
HER2/neu antibodies (6.25 mg/ml) were used to determine
the level of p185HER2/neu.
FACScan Analysis
Analysis of cell cycle distribution after transfection with
siRNA was carried out using a Becton Dickinson FACScan
(BD Bioscience, Heidelberg, Germany). Cells were har-
vested, washed with PBS, and probed with CycleTEST
PLUS DNA reagent kit (Becton Dickinson) according to the
Silencing the HER2/neu Gene Faltus et al. 787
Neoplasia . Vol. 6, No. 6, 2004
manufacturer’s protocol. For each treatment, 30,000 cells
were analyzed. Cell cycle distribution in percentage was
calculated using ModFit LT for Mac (BD Bioscience).
Apoptosis Assays
Cells were treated with siRNA-2 or siRNA-S2 at 5.6 nM
for 96 hours. As apoptosis-positive controls, MCF-7 cells
were treated with campothecin (Sigma-Aldrich, Steinheim,
Germany) at 10 mM for 16 hours. Apoptosis assay was
performed using Vybrant kit according to the manufacturer’s
instructions (Molecular Probes, Leiden, The Netherlands).
Briefly, cells were stained with 3 ml of Annexin V and 1 ml of
propidium iodide (PI; 1 mg/ml) in 100 ml of Annexin V binding
buffer [10 mM HEPES (pH 7.4), 140 mM NaCl, and 5 mM
CaCl2] and incubated for 15 minutes at room temperature in
the dark. Subsequently, 400 ml of binding buffer was added
and mixed gently. The cells were then analysed by flow
cytometry.
Results
Expression of HER2/neu mRNA and Protein in Breast
Cancer Cell Lines
We analyzed HER2/neu expression in four breast cancer
cell lines to select the most appropriate cell lines for the
experiments. Northern blots showed abundant expression of
a 4.5-kb HER2/neu transcript in SK-BR-3 and BT-474 cells
and minimal expression of HER2/neu transcripts in MCF-7
and MDA-MB-468 cells (Figure 1a). These findings were
corroborated by Western blot analysis of p185HER2/neu ex-
pression in these cell lines, standardized to b-actin expres-
sion (Figure 1b), which showed high levels of p185HER2/neu in
SK-BR-3 cells, markedly lower levels in BT-474 cells, and a
faint band in MCF-7 cells. p185HER2/neu expression was
below the limit of detection in MDA-MB-468 cells.
Specific Inhibition of HER2/neu mRNA and Protein
Expression by HER2/neu–Specific siRNA
We next tested the ability of HER2/neu–specific siRNA to
reduce the endogenous level of HER2/neumRNA in SK-BR-
3, BT-474, and MCF-7 breast cancer cells. We transfected
cells with four different HER2/neu–specific siRNA and with
scrambled versions of siRNA-2 (siRNA-S2) and siRNA-4
(siRNA-S4) as controls. After 24 hours, HER2/neu mRNA
levels were moderately decreased in SK-BR-3 cells trans-
fected with one of the four HER2/neu–specific siRNA
(siRNA-1, siRNA-2, siRNA-3, and siRNA-4), and, after 48
hours, HER2/neu mRNA levels were 15% to 85% of the levels
seen in mock-transfected cells (Figure 2a). BT-474 and
MCF-7 cells transfected with HER2/neu–specific siRNA-1
to siRNA-4 showed also reductions in HER2/neu transcripts
at both time points (Figure 2, b and c). The four HER2/neu–
specific siRNA had different abilities to alter the levels of the
corresponding transcripts, with reductions in BT-474 cells or
MCF-7 cells transfected with the different siRNA ranging
from 20% to 42%, or from 7% to 60%, respectively, of the
transcript levels seen in mock-treated cells after 48 hours. In
all cell lines examined, strong reduction of the HER2/neu
mRNA was achieved by transfection with siRNA-2 and, to a
lesser extent, with siRNA-4. Mock-transfected cells or cells
transfected with the scrambled siRNA-S2 or siRNA-S4
exhibited only a slight reduction of HER2/neu mRNA.
Western blot analysis of p185HER2/neu levels in trans-
fected SK-BR-3, BT-474, and MCF-7 cells showed de-
creased protein levels consistent with the results of
Northern blot analyses in these cells (Figure 3). SK-BR-3
cells transfected with siRNA-1 to siRNA-4 showed reduc-
tions of p185HER2/neu compared to the expression in mock-
transfected cells 48 hours after transfection, with a clear
reduction observed after transfection with siRNA-2 (Figure
3a). With all transfections, downregulation of p185HER2/neu in
SK-BR-3 cells increased over time. In BT-474 and MCF-7
cells, reduction of transcript levels correlated also with a
decrease of p185HER2/neu levels (Figure 3, b and c). Depend-
ing on the HER2/neu–specific siRNA administered, a reduc-
tion of p185HER2/neu levels to 3% to 50% in BT-474 cells and
to 29% to 83% in MCF-7 cells compared to the expression in
mock-transfected cells was observed. siRNA-2 at a concen-
tration of 56 nm reduced strongly p185HER2/neu expression in
MCF-7 cells (Figure 3c), which constitutively express only a
low level of HER2/neu expression.
To improve the uptake of siRNA at a concentration of 56
nM, we increased the Oligofectamine concentration from
0.73% to 2.9% (vol/vol) per transfection and observed great-
er inhibition of HER2/neu–specific siRNA in BT-474 cells
compared to mock-transfected cell (data not shown). This
result suggests that optimal liposomal encapsulation is crit-
ical for efficient RNAi-mediated gene silencing. We then
examined lower concentrations of siRNA-2 (5.6 and
0.56 nM) in SK-BR-3 cells and found that transfection with
Figure 1. Expression of (a) HER2/neu mRNA and (b) p185HER2/neu,
in SK-BR-3, BT-474, MCF-7, and MDA-MB-468 cells. (a) HER2/neu mRNA
was subjected to Northern blot analyses. (b) Western blot analyses of
p185HER2/neu expression. To control for variability of loading and transfer,
Northern and Western blot analysis membranes were reprobed for -actin,
and actin-normalized HER2/neu expression was compared. The exposure
time was about 15 seconds.
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siRNA-2 at a concentration of 5.6 nM [and with 0.73% (vol/
vol) Oligofectamine] resulted in inhibition of p185HER2/neu
expression that was at least as strong as the inhibition
achieved with 56 nM siRNA-2 (Figure 3d ). The least effective
of the three siRNA-2 concentrations tested for the down-
regulation of HER2/neu expression was 0.56 nM.
Analysis of HER2/neu Expression by Immunofluorescence
Staining
To evaluate the data from our Western blot experiments,
we further performed an immunofluorescence analysis of
different breast cancer cell lines. As illustrated in Figure 4,
untreated SK-BR-3 and BT-474 cells showed strong levels of
p185HER2/neu staining, whereas signal intensity in MCF-7
cells was weak (data not shown). We tested the ability of
siRNA to reduce the endogenous level of HER2/neu immu-
nofluorescence in SK-BR-3 and BT-474 cells. Twenty-four
hours after transfection of SK-BR-3 and BT-474 cells with
siRNA-2, HER2/neu–specific immunofluorescence was di-
minished, with complete disappearance of staining in SK-
BR-3 and BT-474 cells 96 hours after transfection (Figure 4).
By contrast, no reductions in expression of HER2/neu pro-
tein in vitro were detected in SK-BR-3 or BT-474 cells
between 24 and 96 hours after mock transfection or trans-
fection with the scrambled siRNA-2S.
The Antiproliferative Effect of HER2/neu–Specific siRNA Is
Pronounced in HER2/neu–Overexpressing Breast Cancer
Cells
Because inhibition of HER/neu mRNA expression in
human breast cancer cells can result in a significant dose-
dependent suppression of p185HER2/neu levels, we next
investigated the impact of siRNA transfection on cell prolif-
eration in SK-BR-3, MCF-7, and MDA-MB-468 breast cancer
cells. Considering the limited half-life of siRNA in living cells,
we did not test the biologic activity of HER2/neu–specific
siRNA in BT-474 cells, which have a doubling time of
approximately 100 hours.
We observed a positive correlation between the transfec-
tion of siRNA on HER2/neu expression and biologic effects
in SK-BR-3 breast cancer cell proliferation: SK-BR-3 cells
transfected with one of the HER2-targeted siRNA showed
significant inhibition of proliferation 96 hours after transfection
(siRNA-1: 66.8%; siRNA-2: 56.0%; siRNA-3: 82.9%; siRNA-
4: 70.1%) compared to mock-transfected cells (P V .01)
(Figure 5). The data indicated that the antiproliferative effects
of HER2/neu–directed siRNA were sequence-specific.
Most of the siRNA tested had also an effect on the prolif-
eration of MCF-7 cells, which have low constitutive levels of
HER2/neu expression. After transfection with siRNA-1,
siRNA-2, or siRNA-4, proliferation of MCF-7 cells was re-
duced to 85.9%, 67.0%, or 69.5% of that of mock-transfected
Figure 2. Northern blot analyses of HER2/neu mRNA expression after
transfection with HER2/neu–specific siRNA in (a) SK-BR-3, (b) BT-474, and
(c) MCF-7 cells. HER2/neu mRNA was subjected to Northern blot analysis 24
and 48 hours after the beginning of transfection with 56 nM siRNA. To control
for variability of loading and transfer, membranes were reprobed for human
-actin, and -actin –normalized HER2/neu mRNA levels were compared.
Control cells () were incubated with serum-free medium. OPTI-MEM I alone
and control cells (+) were incubated with OPTI-MEM I plus Oligofectamine
but no siRNA. Breast cancer cells were treated with siRNA-1, siRNA-2,
siRNA-3, or siRNA-4. Furthermore, cells were transfected with control siRNA-
S2 or siRNA-S4.
Figure 3. Western blot analyses of p185HER2/neu, cyclin B1, and cdc2
expression in (a) SK-BR-3, (b) BT-474, and (c) MCF-7 cells after transfection
with HER2/neu–specific siRNA. Western blot analyses were carried out
24 and 48 hours after the beginning of transfection with 56 nM siRNA. The
exposure time for (c) was about 20 minutes due to low expression of HER2/
neu in MCF-7 cells. (d) Western blot of SK-BR-3 cells 48 hours after
transfection with different concentrations (0.56, 5.6, and 56 nM) of siRNA-2 or
its equivalent control siRNA-S2. -Actin was used to control for variability of
loading and transfer in (a) – (d). Subsequently, -actin –normalized protein
levels were compared.
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control cells (Figure 5). It was noted that transfection with
siRNA-3 exerted a strong antiproliferative effect in MCF-7
cells, reducing the proliferation to 24.8% compared to mock-
transfected cells, despite a lack of efficacy in silencing HER2/
neu expression in MCF-7 cells (Figures 2 and 3).
In contrast to SK-BR-3 cells, transfection with different
HER2/neu–specific siRNA did not affect cellular proliferation
of MDA-MB-468 cells, which express almost no HER2/neu
(Figure 5).
Treatment of p185HER2/neu–Overxpressing Cells with HER2/
neu–Specific siRNA Induces G0/G1 Arrest and Correlates
with Downregulation of Cyclin B1
To study the antiproliferative effect exerted by HER2/
neu–specific siRNA in more detail, we analyzed the cell
cycle distribution of siRNA-treated cells. Seventy-two hours
of transfection of SK-BR-3 and BT-474 cells with siRNA-2
resulted in an increase in the proportion of cells in G0/G1
phase, compared to mock-transfected control cells
Figure 4. Immunofluorescence analyses of SK-BR-3 and BT-474 cells treated with 56 nM siRNA-2. Control cells () were incubated with OPTI-MEM I alone and
control cells (+) were incubated with OPTI-MEM I plus Oligofectamine but no siRNA. Cells were treated with siRNA-2 or with siRNA-S2. Ninety-six hours after the
beginning of transfection, cells were analyzed for p185HER2/neu (red) and subsequently for DNA by DAPI staining (blue). Lower panels show the merging of
p185HER2/neu (red) and DNA staining (blue).
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(Figure 6). MCF-7 cells transfected with siRNA-2 did not
show a similar antiproliferative response. As expected from
the previous proliferation assays, transfection with siRNA-S2
or siRNA-S4 did not alter the cell cycle distribution compared
to mock-transfected cells (Figure 6).
To verify that cells were blocked at stage G0/G1, we used
Western blot analysis to screen for markers of later stages in
cell cycle progression (Figure 3). As a component of the
maturation-promoting factor, cyclin B1 is a marker of G2/M
progression and was strongly downregulated in SK-BR-3
and BT-474 cells treated with siRNA-2 (Figure 3, a and b). By
contrast, MCF-7 cells treated with siRNA-2 showed almost
complete depletion of p185HER2/neu, but levels of cyclin B1
were unchanged relative to levels of b-actin. A Western blot
analysis of all three cell lines subsequently demonstrated
constitutive expression of cdc2 independent of p185HER2/neu
or cyclin B1 downregulation (Figure 3).
An unexpected finding was that siRNA-3 had a strong
inhibitory effect on the proliferation of MCF-7 cells (Figure 5),
despite having only a very weak ability to downregulate
HER2/neu expression in these cells (Figures 2 and 3).
Furthermore, siRNA-3 treatment resulted in an elevation of
Figure 5. Effect of HER2/neu–specific siRNA on proliferation of SK-BR-3, MCF-7, and MDA-MB-468 cells. Cells were treated with 56 nM siRNA-1, siRNA-2,
siRNA-3, and siRNA-4 or with one of the control siRNA-S2 or siRNA-S4 and cell numbers were counted at indicated time points. Control (K) and control (K+) cells
were incubated as described in Figure 4.
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the percentage of cells in G0/G1 after 72 hours (Figure 6)
together with reduced levels of cyclin B1 protein (Figure 3).
Treatment With HER2/neu–Specific siRNA Induces Apo-
ptosis in p185HER2/neu–Overxpressing Cells
To explore whether the cells arrested in G0/G1 then
progressed to apoptosis, we stained siRNA-2–transfected
cells with Annexin V and PI and analyzed the cells using flow
cytometry. As illustrated in Figure 7, more than 17% of SK-
BR-3 cells transfected with siRNA-2 were Annexin-positive
compared to only 6% of SK-BR-3 cells transfected with the
scrambled siRNA-S2. Distribution of mock-transfected SK-
BR-3 was similar to that of siRNA-S2–transfected cells. Late
stage of apoptosis (both Annexin-positive and PI-positive)
was not observed in SK-BR-3 cells even 96 hours posttrans-
fection, which is in line with the date from a recent publication
[44]. In contrast to the results seen with SK-BR-3 cells, no
Annexin-positive cells were observed following transfection
of siRNA-2 into MDA-MB-468, without detectable HER2/neu
expression, or MCF-7 cells, with low constitutive levels of
HER2/neu expression (Figure 7a). To show that apoptosis
could be induced in those two cell lines, which were not
affected with the treatment of siRNA-2, MCF-7 cells were
selected and treated with exogenic apoptotic stimulator
campothecin. After exposure to campothecin for 16 hours,
MCF-7 cells displayed 7% of Annexin-positive cells and 10%
of PI-positive cells, compare to 3% and 6%, respectively, in
control nontreated MCF-7 cells (data not shown). Further-
more, apoptosis after siRNA treatment in SK-BR-3 cells was
corroborated by Western blot analysis using specific anti-
bodies against pro-caspase 3 (32 kDa), which is a precursor
of caspase 3. The cellular extracts from siRNA-2–treated
SK-BR-3 cells showed less pro-caspase 3 compared to
mock-treated cellular lysates [control(+)], whereas scram-
bled siRNA-S2 scarcely exhibited effects (Figure 7b). Further
quantification of the bands from the Western blot standard-
ized with loading control b-actin showed a reduction of 18%
of pro-caspase 3 protein in siRNA-2–treated cells compared
to control (+) cells. The results suggested that the down-
regulation of HER2/neu with siRNA-2 in SK-BR-3 cells led to
an activation of apoptosis pathway by showing the cleavage
of pro-caspase 3 to its active form caspase 3. Collectively,
the data from Annexin staining and reduction of pro-caspase
3 protein demonstrated that siRNA-2 targeting of HER2/neu
induced specific apoptosis in SK-BR-3 cells.
Discussion
Amplification and overexpression of the HER/neu proto-
oncogene is found in a number of human malignancies and
human cancer cell lines, and has been correlated with
decreased time to relapse and decreased overall survival
in subsets of patients with breast, ovarian, or certain other
cancers [2–6]. As a transmembrane growth factor receptor
with an extracellular ligand-binding domain, p185HER2/neu is
an appropriate target for monoclonal antibody therapy of
Figure 6. Effect of HER2/neu–specific siRNA on cell cycle distribution of SK-BR- 3, BT-474, MCF-7, and MDA-MB-468 cells. FACScan analyses 72 hours after
treatment of cells. Control cells () were incubated with serum-free medium. OPTI-MEM I alone and control cells (+) were incubated with OPTI-MEM I plus
Oligofectamine but no siRNA. Cells were treated with 56 nM siRNA-1, siRNA-2, siRNA-3, and siRNA-4 or with one of the control siRNAs-S2 or siRNA-S4.
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human cancers characterized by p185HER2/neu overexpres-
sion. Clinical studies using monoclonal antibodies to target
p185HER2/neu in human breast cancer represent the first
example of the successful translation of results from the
molecular analysis of cancer cells into clinical trials [25–28].
Antibody-based therapeutic interventions have certain
limitations in hindering HER2/neu signalling pathways. The
inhibitory effect of antibodies is restricted to transmembrane
forms of p185HER2/neu, and thus cannot inhibit intracellular
receptors, which may contribute to the increased prolifera-
tion of HER/neu–overexpressing cells prior to exposure of
the p185HER2/neu receptors on the cell membrane [30].
p185HER2/neu–specific antibodies might be neutralized by
the extracellular domain of the receptor shed from the
membrane into the surrounding medium. Brodowicz et al.
[30] have demonstrated that this mechanism seems to
interfere with the impact of monoclonal antibodies in vitro,
and the presence of antigenic p185HER2/neu–specific frag-
ments found in patient serum correlates with a poor clinical
response to p185HER2/neu–specific antibodies [31]. Trastu-
zumab, the only monoclonal antibody currently approved for
treatment of breast cancer, has a cytostatic—rather than a
cytotoxic—action on breast cancer cells in vitro [26,32]. The
activity of trastuzumab was found to depend in vivo on the
engagement of Fc receptor–expressing lymphocytes [33],
indicating antibody-dependent cell cytotoxicity as a major
determinant of antibody action. Because monoclonal anti-
bodies targeted to p185HER2/neu may not be effective tools for
the therapeutic manipulation of HER2/neu signalling in every
case, alternative approaches need to be explored for the
inhibition of neoplastic proliferation.
An alternative method of selectively inhibiting gene ex-
pression is the use of antisense oligonucleotides (ASOs)
[34]. Various studies using ASOs to inhibit HER2/neu gene
expression in human breast cancer cells showed significant
dose-dependent suppression of p185HER2/neu levels and
suppression of cancer cell growth [35–39]. Antiproliferative
effects of HER2/neu–specific ASOs were seen in HER2/
neu–overexpressing breast cancer cells transfected with
ASOs at concentrations between 1 and 20 mM [36,39]. In
addition, HER2/neu antisense treatment inhibited cellular
proliferation in p185HER2/neu–overexpressing cancer cells of
different histologic origin, such as ovarian, lung, and pan-
creatic cells [38]. Still, ASOs have limited therapeutic po-
tential due to toxicities and side effects likely arising from
inhibition through other mechanisms [40]. Currently, the
only approved ASO therapy is the one for CMV retinitis
because ASOs are confined to a very small compartment
(intraocular injection) to reach relatively high concentra-
tions. Whether high plasma levels of ASOs, which are
needed to inhibit HER2/neu, can be systemically reached
in breast cancer patients without severe side effects
remains to be elucidated.
Gene expression can also be regulated by exploiting
elements of the RNAi machinery. Elbashir et al. [17] have
shown that transient transfection of synthetic siRNA can
downregulate target genes in mammalian cells. siRNA as
tools for therapeutic interventions must be specific for the
gene of interest, but for a given gene, only certain siRNA are
efficient for gene silencing. We exploited this technique to
study the role of HER2/neu in the proliferation of human
cancer cells exhibiting different levels of HER2/neu over-
expression.
Our analysis revealed that transfection of human breast
cancer cells with siRNA targeted to HER2/neu downregu-
lates corresponding transcripts in cell culture. In our study,
siRNA-2 and siRNA-4 exerted the most pronounced effect
on the level of HER2/neu expression. However, all cell lines
tested in our study underwent gene silencing of HER2/neu
after treatment with HER2/neu–specific siRNA, regardless
of baseline HER2/neu expression. As expected, the scram-
bled forms of siRNA-2 and siRNA-4 had very little effect on
HER2/neu expression.
siRNA-2 had an antiproliferative effect in breast cancer
cells showing high levels of HER2/neu expression (BT-474
and SK-BR-3). siRNA-2 exerted also antiproliferative effect
to a lesser extent in MCF-7 cells, a cell line with low levels of
HER2/neu expression. By contrast, we could not detect
inhibitory impacts of proliferation in MDA-MB-468 cells,
which express scarcely HER/neu. Taken together, the data
Figure 7. Effect HER2/neu–specific siRNA on apoptosis induction in MDA-MB-468, MCF-7, and SK-BR-3 cells. (a) Cells were treated with 5.6 nM siRNA-2
or siRNA-S2. Control cells C () were incubated with serum-free medium OPTI-MEM I alone. C (+) cells were additionally treated with Oligofectamine but without
siRNA. Ninety-six hours after transfection, cells were analysed for early apoptosis by Annexin staining (Vybrant apoptosis kit). (b) SK-BR-3 cells were treated with
siRNA-2 or its scrambled form for 96 hours. Western blot analysis was performed by using specific antibodies against pro-caspase 3. The same membrane was
stained with antibodies against -actin as loading controls.
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suggest that the antiproliferative effect of siRNA is associat-
ed with the expression level of HER2/neu in breast cancer
cells.
HER2/neu–independent mechanisms may explain the
unexpected observation that siRNA-3 had only a very weak
potential to inhibit HER/neu expression in MCF-7 cells yet
still inhibits cell proliferation. A recent report described off-
target effects exerted by a core of sequence similarity to the
3V end of the siRNA sense strand [41]. To address the
question of whether short stretches of identity to siRNA-3
exerted siRNA-specific rather than target-specific signatures
in our analysis, we aligned both sense and antisense
strands, as well as subfragments thereof, to the databank
(GenBank, EMBL, April 2004), but no significant homologies
were detectable. Thus, there is no obvious explanation for
the effect of siRNA-3 in MCF-7 cells including G0/G1 arrest,
downregulation of cyclin B1, and its inhibition of proliferation.
We are going to reduce the concentration of siRNA-3 and
further examine the impact on G1/S molecules in MCF-7
cells. The observation also suggested that further studies
are required to explore the working mechanisms of siRNA in
more detail, and a careful selection and examination of
siRNA for gene silencing is a cardinal requirement for a
target-specific gene silencing through RNAi.
During the preparation of this report, two studies evalu-
ating the RNAi-based gene silencing of the HER2/neu gene
using synthetic siRNA or a retrovirus-mediated expression of
hairpin RNA, both directed against theHER2/neu gene, were
published [42,43]. In agreement with our results, both studies
suggest that HER2/neu depletion in HER2/neu–overex-
pressing breast cancer cells inhibits their proliferation. Still,
these reports provide a different view on the cell cycle
distribution of treated cells: Although Choudhury et al. [42]
describe growth arrest at G1/S, Yang et al. [43] observed
increased G0/G1 arrest at a level similar to that seen in our
studies. Consistent with the our results seen with G0/G1
arrest, transfection with siRNA-2 promoted HER2/neu–
induced apoptosis only in high-expressing SK-BR-3 cells,
and not in MCF-7 or MD-MB-468 cells, suggesting that the
induced apoptosis was specific and dependent on the re-
duction of HER2/neu in HER2/neu–overexpressing cells.
Taken together, compared to antibody- or antisense-
mediated methods for the inhibition of HER2/neu signaling,
gene silencing through siRNA combines two major advan-
tages: 1) strong and specific downregulation of HER2/neu
expression at very low concentrations; and 2) siRNA treat-
ment, which exerts a cytotoxic effect in HER2/neu–over-
expressing cells. Translation of these promising in vitro
results into therapies for human disease faces some ob-
stacles. Despite the success of siRNA-mediated strategies
in silencing gene expression in cultured cells, unmodified
siRNA does not seem to be effective at reducing target gene
expression in murine tissues after systemic administration,
unless applied by hydrodynamic injection in relatively large
nonphysiological volumes of saline [44]. siRNA-mediated
effects in living animals described in early reports are re-
stricted to hepatocytes. Until chemical modifications can be
developed to improve the utility of siRNA, alternative strate-
gies such as vector-driven expression of hairpin RNA are
required for the inhibition of tumor growth in vivo [45].
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